{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:15:23Z","timestamp":1778915723597,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2017.00569","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T12:17:04Z","timestamp":1509365824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity\u2014Report of a Case and Review of the Literature"],"prefix":"10.3389","volume":"8","author":[{"given":"Julian","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Mult Scler"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles","year":"2006","journal-title":"J Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol"},{"key":"B9","unstructured":"GhodasaraRS\n            SmithSRS\n            MosleyM\n            MorganR\n            BowerM\n            KaganL\n          Serious Adverse Events (SAE), Autoimmunity (AI), and Infections\u2026 by Dr. Samuel F. Hunter2017"},{"key":"B10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.14310\/horm.2002.1501","article-title":"Graves\u2019 disease after treatment with alemtuzumab for multiple sclerosis","volume":"14","author":"Tsourdi","year":"2015","journal-title":"Horm Athens Greece"},{"key":"B11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD002127","DOI":"10.1002\/14651858.CD002127.pub3","article-title":"Mitoxantrone for multiple sclerosis","author":"Martinelli Boneschi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1517\/14740338.6.2.183","article-title":"The safety profile of cyclophosphamide in multiple sclerosis therapy","volume":"6","author":"Perini","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.0022-202X.2005.23692.x","article-title":"Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)\/CD25(-) cells promote systemic alopecia areata and CD4(+)\/CD25(+) cells blockade disease onset in the C3H\/HeJ mouse model","volume":"124","author":"McElwee","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.15537\/Smj.2016.6.13777","article-title":"Severe subtype of alopecia areata is highly associated with thyroid autoimmunity","volume":"37","author":"Bin Saif","year":"2016","journal-title":"Saudi Med J"},{"key":"B18","first-page":"123","article-title":"Thyroid autoimmunity in patients with alopecia areata","volume":"16","author":"Kasumagi\u0107-Halilovi\u0107","year":"2008","journal-title":"Acta Dermatovenerol Croat"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1210\/jc.2014-3985","article-title":"Organ specificity in autoimmune diseases: thyroid and islet autoimmunity in alopecia areata","volume":"100","author":"Noso","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1468-3083.2006.01676.x","article-title":"Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history","volume":"20","author":"Goh","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1600-0404.1990.tb00928.x","article-title":"Multiple sclerosis and other immunologic diseases","volume":"81","author":"Seyfert","year":"1990","journal-title":"Acta Neurol Scand"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S0025-6196(11)63913-X","article-title":"Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989","volume":"70","author":"Safavi","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1046\/j.1365-4362.2002.01357.x","article-title":"The pattern and profile of alopecia areata in Singapore \u2013 a study of 219 Asians","volume":"41","author":"Tan","year":"2002","journal-title":"Int J Dermatol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T12:17:06Z","timestamp":1509365826000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2017.00569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":26,"alternative-id":["10.3389\/fneur.2017.00569"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2017.00569","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]},"article-number":"569"}}